2025-520519-14-00
Recruiting
Phase 3
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event
Overview
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- AstraZeneca AB
- Enrollment
- 3,531
- Locations
- 299
- Primary Endpoint
- Time to first event of any component of MACE PLUS
Overview
Brief Summary
To compare the effect of treatment with AZD0780 to placebo in reducing the risk of MACE-PLUS (the composite of CV death, myocardial infarction [MI], ischaemic stroke, acute lower limb ischemia, major amputation of a vascular aetiology, and urgent arterial revascularisation)
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Meets one of the following: (a) Participants with history of an ASCVD event: Participants ≥ 18 years of age at the time of signing the ICF with a history of ASCVD defined as ACS within 1 to 12 months prior to randomisation, or large artery ischaemic stroke suspected to be due to atherosclerotic vascular disease within 1 to 12 months prior to randomisation, or revascularisation for symptomatic lower limb PAD, and LDL-C ≥ 60 mg/dL (≥ 1.55 mmol/L). Additional risk factors based on the level of the screening LDL-C: o Participants with an LDL-C ≥ 75 mg/dL (≥ 1.9 mmol/L) need to have at least one of the other additional risk factors (i to viii) below. i) T2DM requiring ongoing medical therapy ii) Age ≥ 65 years v) Previous above ankle amputation due to PAD vi) Previous diagnosis of non-end stage CKD (b) Participants at increased risk of a first ASCVD event: Male participant ≥ 50 years of age or female participant ≥ 55 years of age at the time of signing the ICF with LDL-C ≥ 100 mg/dL (≥ 2.6 mmol/L) and diagnostic evidence of at least one of the following disease categories (i, ii, or iii): i) Significant atherosclerotic artery disease ii) High-risk Type 1 or Type 2 diabetes mellitus with manifestation of end-organ disease (diabetic nephropathy, retinopathy, neuropathy or an ABI outside the normal range [0.9 to 1.4]) iii) Documented atherosclerosis of less significance For ii) and iii), participants need to have at least one of the additional risk factors below: a) CKD with eGFR ≤ xx mL/min/1.73 m2 b) Current tobacco use c) Age ≥ 65 d) T2DM (if included on the less significant atherosclerosis criterion iii)
- •Participant should be receiving a maximally tolerated lipid-lowering regimen including a maximally tolerated dose of a statin. (a) Participants who are judged by the treating physician not to tolerate high-intensity statins (according to guidelines, typically, atorvastatin ≥ 40 mg once daily or rosuvastatin ≥ 20 mg once daily) may be included if treated with a low or moderate intensity statin dose. (b) Participants not receiving any statins must have documented intolerable side effects to at least 2 different statins, including one at the lowest standard dose or on a chronic medication that would prohibit the use of a statin (according to the prescribing information for the statin in question). (c) Participants must achieve a stable dose (> 28 days) of lipid-lowering therapies before screening.
Exclusion Criteria
- •Any underlying known disease, or condition including homozygous familial hypercholesterolaemia, or LDL or plasma apheresis within 12 months prior to randomisation, that, in the opinion of the investigator, might interfere with the interpretation of the clinical study results.
- •Use of PCSK9 inhibitors: evolocumab/alirocumab within 12 weeks of the Screening Visit or planned use during the study, or inclisiran within 18 months of the Screening Visit or planned use during the study, or any other approved PCSK9 inhibitor use within 5 half lives prior to the Screening Visit or planned use during the study.
- •Any revascularisation procedure planned within the next 3 months.
- •Available imaging assessment within the last 3 years showing either coronary calcium score of zero, or a coronary computed tomography angiography with no atherosclerosis.
- •Calculated eGFR < 15 mL/min/1.73 m2 (CKD-EPI formula; Delgado et al 2022, Inker et al 2021) at screening.
- •Any laboratory values with the following deviations at screening: - AST or ALT > 3 × ULN - TBL > 2 × ULN (except for participants with Gilbert's syndrome where TBL 3 × ULN is acceptable provided direct bilirubin < 1.5 × ULN) - Fasting triglycerides ≥ 400 mg/dL (≥ 4.52 mmol/L) - Creatine kinase > 5 × ULN - Urine albumin/creatinine ratio ≥ 500 mg/g
- •Uncontrolled T2DM defined as HbA1c ≥ 9.5% at screening.
- •Inadequately treated hypothyroidism defined as TSH > 1.5 × ULN at screening or participants whose thyroid replacement therapy was initiated or modified within the last 3 months prior to screening.
- •Use of mipomersen or lomitapide (cholesterol-lowering medications) within 12 months of screening or planned use during the study.
- •Use of gemfibrozil within one week prior to the Screening Visit or planned use during the study.
Outcomes
Primary Outcomes
Time to first event of any component of MACE PLUS
Time to first event of any component of MACE PLUS
Secondary Outcomes
- Time to first event of any component of 3P MACE
- Time to first event of any component of MACE PLUS in participants with a prior history of ASCVD
- Time to first event of MI
- Time to first event of urgent coronary revascularisation
- Time to CV death
- Time to first event of MALE
- Time to all-cause mortality
Investigators
AstraZeneca Clinical Study Information Center
Scientific
AstraZeneca AB
Study Sites (299)
Loading locations...
Similar Trials
Recruiting
Not Applicable
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)NCT07261644Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.500
Active, not recruiting
Phase 3
一项评估 AZD0780 在有 ASCVD 事件史或首次发生 ASCVD 事件高风险的患者中对重大 CV 不良事件的作用的 III 期研究CTR202537231,195
Active, not recruiting
Phase 3
一项评估 AZD0780 在有 ASCVD 事件史或首次发生 ASCVD 事件高风险的患者中对重大 CV 不良事件的作用的 III 期研究CTR202537231,195
Active, not recruiting
Phase 3
一项评估 AZD0780 在有 ASCVD 事件史或首次发生 ASCVD 事件高风险的患者中对重大 CV 不良事件的作用的 III 期研究CTR202537231,195
Completed
Phase 2
Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) PatientsType II Diabetes MellitusNCT01020123AstraZeneca530